Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/25477
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRic Priceen_US
dc.contributor.authorFrançois Nostenen_US
dc.contributor.authorJulie A. Simpsonen_US
dc.contributor.authorChristine Luxemburgeren_US
dc.contributor.authorLucy Phaipunen_US
dc.contributor.authorFeiko Ter Kuileen_US
dc.contributor.authorMichele Van Vugten_US
dc.contributor.authorTan Chongsuphajaisiddhien_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherJohn Radcliffe Hospitalen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKenya Medical Research Instituteen_US
dc.date.accessioned2018-09-07T08:52:09Z-
dc.date.available2018-09-07T08:52:09Z-
dc.date.issued1999-01-01en_US
dc.identifier.citationAmerican Journal of Tropical Medicine and Hygiene. Vol.60, No.6 (1999), 1019-1023en_US
dc.identifier.issn00029637en_US
dc.identifier.other2-s2.0-0032985269en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0032985269&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/25477-
dc.description.abstractThe factors affecting the development of patent Plasmodium falciparum gametocytemia were assessed in 5,682 patients entered prospectively into a series of antimalarial drug trials conducted in an area of low and seasonal transmission on the western border of Thailand. Of the 4,565 patients with admission thick smear assessments, 110 (2.4%) had gametocytemia. During the follow-up period 170 (3%) of all patients developed patent gametocytemia, which in 89% had developed by day 14 following treatment. In a multiple logistic regression model five factors were found to be independent risk factors at presentation for the development or persistence of gametocytemia during follow up; patent gametocytemia on admission (adjusted odds ratio [AOR] = 7.8, 95% confidence interval [CI] = 3.7-16, P < 0.001), anemia (hematocrit <30%) (AOR = 3.9, 95% CI = 2.3-6.5, P < 0.001), no coincident P. vivax malaria (AOR = 3.5, 95% CI = 1.04-11.5, P < 0.04), presentation with a recrudescent infection (AOR - 2.3, 95% CI = 1.3-4.1, P < 0.004), and a history of illness longer than two days (AOR = 3.3, 95% CI = 1.7-6.6, P < 0.001). Patients whose infections responded slowly to treatment or recrudesced subsequently were also more likely to carry gametocytes than those who responded rapidly or were cured (relative risks = 1.9, 95% CI = 1.3-2.7 and 2.8, 95% CI 2.0-4.0, respectively; P < 0.001). These data provide further evidence of important epidemiologic interactions between P. falciparum and P. vivax, and drug resistance and transmission potential.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0032985269&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleRisk factors for gametocyte carriage in uncomplicated falciparum malariaen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.4269/ajtmh.1999.60.1019en_US
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.